

para pacientes y familiares




Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) https://nej.md/45X0Nuc
Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer https://nej.md/4e6T0fr
#Oncology
Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further trials are needed to improve prediction tools. https://ja.ma/4nxCnO9
In patients 70 years and older undergoing surgical treatment for oropharyngeal carcinoma, HPV-positive status determined by p16 positivity was associated with improved survival outcomes. https://ja.ma/4lEhVtn
Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) https://nej.md/45X0Nuc
Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer https://nej.md/4e6T0fr
#Oncology
Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further trials are needed to improve prediction tools. https://ja.ma/4nxCnO9
In patients 70 years and older undergoing surgical treatment for oropharyngeal carcinoma, HPV-positive status determined by p16 positivity was associated with improved survival outcomes. https://ja.ma/4lEhVtn
Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) https://nej.md/45X0Nuc
Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer https://nej.md/4e6T0fr
#Oncology
Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further trials are needed to improve prediction tools. https://ja.ma/4nxCnO9
In patients 70 years and older undergoing surgical treatment for oropharyngeal carcinoma, HPV-positive status determined by p16 positivity was associated with improved survival outcomes. https://ja.ma/4lEhVtn